Oncura

Atezolizumab + Bevacizumab: what to expect

HepatocellularTaken continuously — no infusion cycle5 effects documented

A combination of immunotherapy and an anti-blood-vessel antibody for liver cancer. Watch for immune-related inflammation (which can affect the liver, bowel, lungs, or glands at any time) and, from bevacizumab, higher blood pressure and bleeding risk.

Immunotherapy (atezolizumab) + anti-angiogenic antibody (bevacizumab) every 3 weeks. Immune-related effects can appear ANY time (not nadir-based), and bevacizumab adds blood-pressure, bleeding, and protein-in-urine risks — so onset is tracked in weeks/months, not infusion days. In liver cancer, an endoscopy to check for varices is usually done before starting bevacizumab.

Get help straight away — this is true on any regimen, on any day.

A temperature of 100.4°F (38°C) or higher during treatment can mean a serious infection while your blood counts are low. Call your team or go to the ER — do not wait it out.

Also urgent: trouble breathing or chest pain · swelling of the face, lips or throat · new confusion or fainting · shaking chills · not being able to keep fluids down.

This is standing guidance shown to everyone. Nothing on this page is based on anything about you, and nobody is monitoring you.

What is reported

This regimen is taken continuously, so effects are described in the terms their sources use rather than by cycle day.

Immune-related hepatitis (liver inflammation)

can occur any time on treatment

Immunotherapy can make the immune system inflame the liver, seen as rising liver blood tests. In liver cancer this is watched closely and distinguished from the disease itself; it may be treated with steroids. Report yellowing skin/eyes or belly pain.

Call your team urgently: Yellowing of skin/eyes, dark urine, or severe belly pain.

reported by about ~7% (immune-mediated) of people; severe in ~3% · from Atezolizumab

Other immune-related effects (colitis, pneumonitis, endocrine, skin)

any time on or after treatment

The immune system can inflame other organs — bowel (diarrhea/colitis), lungs (cough/breathlessness), thyroid or other glands, and skin. These can appear any time, even after treatment. Early reporting lets your team treat them promptly.

Call your team urgently: Severe diarrhea, breathlessness, or feeling very unwell — contact your team urgently.

reported by about varies by organ% of people · from Atezolizumab

High blood pressure (hypertension)

over the first weeks; ongoing

Bevacizumab commonly raises blood pressure. Your team checks it regularly and treats it with medicine so you can stay on therapy.

Call your team: Severe headache, vision changes, or chest pain.

reported by about ~30% of people; severe in 15% · from Bevacizumab

Bleeding / hemorrhage

any time on treatment

Bevacizumab can raise bleeding risk — from minor nosebleeds to, less often, serious bleeding (in liver cancer, from enlarged veins/varices). An endoscopy to check for varices is usually done before starting. Report any significant bleeding at once.

Call your team urgently: Vomiting blood, coughing up blood, or black/tarry stools — emergency.

severe in 6.4% · from Bevacizumab

Protein in urine (proteinuria)

over weeks of treatment

Bevacizumab can cause the kidneys to leak protein, usually found on a urine test. Your team monitors it and may hold the drug if it's high.

reported by about ~20-30% of people; severe in ~3-7% · from Bevacizumab

Where this comes from

  1. S1. Finn RS, IMbrave150 trial (atezolizumab + bevacizumab, HCC) (2020) — PMID 32402160
  2. S2. Atezolizumab (Tecentriq) FDA prescribing information — FDA label
  3. S3. Bevacizumab (Avastin) FDA prescribing information — FDA label

A window appears here only where a retrievable document ties it to a drug in this regimen. Where nothing could be found, the window was removed rather than estimated — so a missing time is an honest gap, not an oversight.

Track your own cycle in Oncura →

Free, no account, nothing leaves your device.